Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
A new drug treating a rare form of blindness will cost $850,000. Photo: Courtesy of Spark Therapeutics
Spark Therapeutics is charging $850,000 for its recently approved gene therapy drug, Luxturna, which treats a rare eye condition that leads to blindness. The actual price will be lower after Spark negotiates discounts with health insurers, but uninsured patients and people with high deductibles and coinsurance rates pay based on the list price.
Why it matters: Luxturna is now the most expensive drug on the market, although many other rare-disease drugs also cost more than $500,000.
More details: The drug company said it is working with insurers to offer rebates if Luxturna doesn't work, and it is talking with the federal government to allow insurers to pay for the therapy over several years instead of having to make one large upfront payment.
Go deeper: The $850,000 price tag for Luxturna is above what is considered to be a fair, value-based price, according to a draft analysis from a group that evaluates drug prices.